[go: up one dir, main page]

BRPI1005919A2 - composição imunogênica - Google Patents

composição imunogênica

Info

Publication number
BRPI1005919A2
BRPI1005919A2 BRPI1005919A BRPI1005919A BRPI1005919A2 BR PI1005919 A2 BRPI1005919 A2 BR PI1005919A2 BR PI1005919 A BRPI1005919 A BR PI1005919A BR PI1005919 A BRPI1005919 A BR PI1005919A BR PI1005919 A2 BRPI1005919 A2 BR PI1005919A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
BRPI1005919A
Other languages
English (en)
Inventor
Nobuo Ida
Reiji Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI1005919A2 publication Critical patent/BRPI1005919A2/pt
Publication of BRPI1005919B1 publication Critical patent/BRPI1005919B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025Nucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1005919-9A 2009-02-27 2010-02-26 Composição imunogênica BRPI1005919B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-045555 2009-02-27
JP2009045555 2009-02-27
PCT/JP2010/053055 WO2010098432A1 (ja) 2009-02-27 2010-02-26 免疫原性組成物

Publications (2)

Publication Number Publication Date
BRPI1005919A2 true BRPI1005919A2 (pt) 2016-02-10
BRPI1005919B1 BRPI1005919B1 (pt) 2021-06-22

Family

ID=42665636

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005919-9A BRPI1005919B1 (pt) 2009-02-27 2010-02-26 Composição imunogênica

Country Status (15)

Country Link
US (1) US9056095B2 (pt)
EP (1) EP2402032B1 (pt)
JP (1) JP6008345B2 (pt)
KR (1) KR20110128284A (pt)
CN (1) CN102333541B (pt)
AU (1) AU2010218752B2 (pt)
BR (1) BRPI1005919B1 (pt)
CA (1) CA2753567C (pt)
DK (1) DK2402032T3 (pt)
ES (1) ES2755361T3 (pt)
HU (1) HUE046865T2 (pt)
MX (1) MX2011008923A (pt)
PL (1) PL2402032T3 (pt)
PT (1) PT2402032T (pt)
WO (1) WO2010098432A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758929B (zh) 2008-06-27 2018-05-25 硕腾有限责任公司 新颖的佐剂组合物
ES2829819T3 (es) * 2010-08-26 2021-06-02 Toray Industries Composición inmunogénica
JPWO2013085021A1 (ja) * 2011-12-09 2015-04-27 株式会社林原 抗体産生増強用の組成物
SG10202011046RA (en) * 2012-09-21 2020-12-30 Intensity Therapeutics Inc Method of treating cancer
CN102988981B (zh) * 2012-12-13 2015-03-04 中国水产科学研究院黄海水产研究所 一种增强爱德华氏菌疫苗免疫接种效果的佐剂及使用方法
KR20190009840A (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX386144B (es) 2013-10-09 2025-03-18 Toray Ind Inc Star Inmunopotenciador.
EP3693011A1 (en) * 2014-04-18 2020-08-12 Auburn University Particulate vaccine formulations for inducing innate and adaptive immunity
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
SI3244920T1 (sl) 2015-01-16 2023-09-29 The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture Cepivo proti slinavki in parkljevki
GB201918963D0 (en) 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
CA3230661A1 (en) 2021-08-30 2023-03-09 Toray Industries, Inc. Composition for enhancing immunogenicity
CN117813112A (zh) 2021-08-30 2024-04-02 东丽株式会社 免疫原性增强用组合物
KR20240065074A (ko) 2021-09-16 2024-05-14 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2600085A1 (en) 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
JP2008088158A (ja) 2006-09-05 2008-04-17 Toray Ind Inc 親水性活性物質含有微粒子の製造方法
JP2008254338A (ja) 2007-04-05 2008-10-23 Bridgestone Corp タイヤの製造方法およびその装置
EP2336173A4 (en) 2008-09-30 2012-07-25 Toray Industries FOR BINDING THE CROP PROTEIN 2 OF THE HEPATITIS C-VIRUS CAPACITIVE ANTIBODY AND METHOD FOR IDENTIFYING THE GENOTYPIC OF THE HEPATITIS C VIRUS USING THEREOF

Also Published As

Publication number Publication date
DK2402032T3 (da) 2019-11-04
CA2753567A1 (en) 2010-09-02
ES2755361T3 (es) 2020-04-22
CA2753567C (en) 2019-12-31
CN102333541A (zh) 2012-01-25
AU2010218752A1 (en) 2011-08-25
EP2402032A4 (en) 2013-05-01
HUE046865T2 (hu) 2020-03-30
KR20110128284A (ko) 2011-11-29
AU2010218752B2 (en) 2015-05-28
CN102333541B (zh) 2014-09-03
MX2011008923A (es) 2011-09-09
US9056095B2 (en) 2015-06-16
PL2402032T3 (pl) 2020-03-31
WO2010098432A1 (ja) 2010-09-02
JP6008345B2 (ja) 2016-10-19
PT2402032T (pt) 2019-11-19
EP2402032B1 (en) 2019-08-14
JPWO2010098432A1 (ja) 2012-09-06
US20110300223A1 (en) 2011-12-08
BRPI1005919B1 (pt) 2021-06-22
EP2402032A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
BRPI1015474A2 (pt) composição
HRP20181347T1 (hr) Formulacije dvoslojne tablete
UY33161A (es) Composiciones plaguicidas
LT3431076T (lt) Patobulinta lipidinė kompozicija
DK3097925T3 (da) Farmaceutisk sammensætning
DOP2011000396A (es) Composiciones novedosas
BRPI1004940A2 (pt) composição farmacêutica
BRPI1010301A2 (pt) composição.
BRPI1005919A2 (pt) composição imunogênica
EP2488586A4 (en) HARDENING COMPOSITION
EP2495286A4 (en) HARDENING COMPOSITION
BRPI1010690A2 (pt) composições
BRPI1015939A2 (pt) composição farmacêutica
BRPI1009465A2 (pt) Formulação
PL2393476T3 (pl) Kompozycje resweratrolu
EP2515938A4 (en) IMMUNOGENIC COMPOSITIONS
EP3348251C0 (en) SUN PROTECTION COMPOSITIONS
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
BRPI1005290A2 (pt) composição
EP2394634A4 (en) COMPOSITION CONTAINING HESPERIDINE
SMT202100150T1 (it) Formulazioni migliorate

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/39 (2006.01), A61K 47/60 (2017.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09X Decision of grant: republication
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.